{"id":472,"date":"2024-04-14T19:47:30","date_gmt":"2024-04-14T19:47:30","guid":{"rendered":"https:\/\/vicare.ar\/?p=2537"},"modified":"2024-07-08T15:07:19","modified_gmt":"2024-07-08T15:07:19","slug":"novedades-en-el-tratamiento-del-cancer-renal-prostata-y-veji","status":"publish","type":"post","link":"https:\/\/vicare.ar\/eng\/novedades-en-el-tratamiento-del-cancer-renal-prostata-y-veji\/","title":{"rendered":"Novedades en el tratamiento del c\u00e1ncer de ri\u00f1\u00f3n, prostata y vejiga"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"472\" class=\"elementor elementor-472\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-994ef06 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"994ef06\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-34ec148\" data-id=\"34ec148\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-88c4029 elementor-arrows-position-inside elementor-pagination-position-outside elementor-widget elementor-widget-image-carousel\" data-id=\"88c4029\" data-element_type=\"widget\" data-settings=\"{&quot;slides_to_show&quot;:&quot;1&quot;,&quot;navigation&quot;:&quot;both&quot;,&quot;autoplay&quot;:&quot;yes&quot;,&quot;pause_on_hover&quot;:&quot;yes&quot;,&quot;pause_on_interaction&quot;:&quot;yes&quot;,&quot;autoplay_speed&quot;:5000,&quot;infinite&quot;:&quot;yes&quot;,&quot;effect&quot;:&quot;slide&quot;,&quot;speed&quot;:500}\" data-widget_type=\"image-carousel.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-image-carousel-wrapper swiper\" dir=\"ltr\">\n\t\t\t<div class=\"elementor-image-carousel swiper-wrapper\" aria-live=\"off\">\n\t\t\t\t\t\t\t\t<div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"1 of 3\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/vicare.ar\/wp-content\/uploads\/2024\/04\/1-Novedades-rinon-768x768.jpg\" alt=\"Novedades C\u00e1ncer\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"2 of 3\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/vicare.ar\/wp-content\/uploads\/2024\/07\/2-Novedades-Prostata-768x768.jpg\" alt=\"2-Novedades-Prostata\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"3 of 3\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/vicare.ar\/wp-content\/uploads\/2024\/07\/3-Novedades-vejiga-768x768.jpg\" alt=\"3-Novedades-vejiga\" \/><\/figure><\/div>\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"elementor-swiper-button elementor-swiper-button-prev\" role=\"button\" tabindex=\"0\">\n\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-eicon-chevron-left\" viewbox=\"0 0 1000 1000\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M646 125C629 125 613 133 604 142L308 442C296 454 292 471 292 487 292 504 296 521 308 533L604 854C617 867 629 875 646 875 663 875 679 871 692 858 704 846 713 829 713 812 713 796 708 779 692 767L438 487 692 225C700 217 708 204 708 187 708 171 704 154 692 142 675 129 663 125 646 125Z\"><\/path><\/svg>\t\t\t\t\t<\/div>\n\t\t\t\t\t<div class=\"elementor-swiper-button elementor-swiper-button-next\" role=\"button\" tabindex=\"0\">\n\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-eicon-chevron-right\" viewbox=\"0 0 1000 1000\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M696 533C708 521 713 504 713 487 713 471 708 454 696 446L400 146C388 133 375 125 354 125 338 125 325 129 313 142 300 154 292 171 292 187 292 204 296 221 308 233L563 492 304 771C292 783 288 800 288 817 288 833 296 850 308 863 321 871 338 875 354 875 371 875 388 867 400 854L696 533Z\"><\/path><\/svg>\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<div class=\"swiper-pagination\"><\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ed15570 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ed15570\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-39ad7d3\" data-id=\"39ad7d3\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-41046eb elementor-widget elementor-widget-text-editor\" data-id=\"41046eb\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<p><strong>C\u00e1ncer de ri\u00f1\u00f3n:<\/strong><br \/>En los primeros congresos del 2024, como el ASCO GU (American Society of Clinical Oncology G\u00e9nito-urinario) desarrollado en San Francisco EEUU, las novedades en el tratamiento del c\u00e1ncer renal se centraron en mostrar los avances significativos logrados con la combinaci\u00f3n de inmunoterapia y terapias dirigidas. Se mostraron datos a largo plazo del beneficio de la combinaci\u00f3n de ipilimumab y nivolumab a 8 a\u00f1os y de nivolumab con cabozantinib a 4 a\u00f1os.<br \/>Estas 2 combinaciones de medicamentos para pacientes con enfermedad<br \/>avanzada son herramientas ya utilizadas en nuestro medio, as\u00ed como otras<br \/>opciones como pembrolizumab con axitinib, pembrolizumab con lenvatinib o bien avelumab con axitinib. Estos resultados en eficacia y seguridad a largo plazo consolidan datos ya presentados desde el 2018.<br \/>En enfermedad localizada, es decir en aquellos pacientes que fueran operados de tumores renales de gran tama\u00f1o o que comprometen ganglios (considerados de alto riesgo de recurrencia), se mostr\u00f3 el beneficio del pembrolizumab con datos que muestran mejores chances de curarse respecto a cirug\u00eda y placebo. Son los primeros datos de beneficio en supervivencia luego de la cirug\u00eda en toda la historia del c\u00e1ncer renal y tratamientos post-operatorios.<\/p><p>C\u00e1ncer de pr\u00f3stata:<br \/>M\u00faltiples novedades han sido desarrolladas a lo largo de los \u00faltimos 5 a\u00f1os en c\u00e1ncer pr\u00f3stata, como la evaluaci\u00f3n de la historia familiar de c\u00e1ncer, donde se han identificado diversos genes con alteraciones significativas, llamadas mutaciones, que conllevan a un riesgo aumentado de c\u00e1ncer no solamente de pr\u00f3stata, sino de otros sitios como colon, mama, ovario y p\u00e1ncreas. En el caso de sospecha de c\u00e1ncer hereditario se puede discutir con su m\u00e9dico de cabecera la posibilidad de realizar asesoramiento gen\u00e9tico. La disponibilidad de los test gen\u00e9ticos es factible en nuestro medio despu\u00e9s de una indicaci\u00f3n responsable del especialista.<\/p><p>C\u00e1ncer de vejiga:<br \/>El tratamiento hist\u00f3rico de los pacientes con c\u00e1ncer de vejiga avanzado no<br \/>quir\u00fargico se bas\u00f3 en quimioterapia con 2 drogas principales como el cisplatino y la gemcitabine. En el congreso europeo del 2023 (ESMO) se presentaron los resultados de la combinaci\u00f3n de inmunoterapia (pembrolizumab) y un f\u00e1rmaco conjugado nuevo llamado enfortumab-vedotin, dirigido contra una mol\u00e9cula expresada por las c\u00e9lulas tumorales de los tumores de vejiga llamada nectina.<br \/>Los resultados han sido superiores a la quimioterapia convencional, constituyendo probablemente en un nuevo est\u00e1ndar de tratamiento para<br \/>pacientes con c\u00e1ncer de vejiga avanzado como primera l\u00ednea o primer<br \/>tratamiento. La evaluaci\u00f3n de su aprobaci\u00f3n deber\u00e1 ser considerada por cada una de las entidades regulatorias de cada pa\u00eds de las distintas regiones del planeta.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>C\u00e1ncer de ri\u00f1\u00f3n:En los primeros congresos del 2024, como el ASCO GU (American Society of Clinical Oncology G\u00e9nito-urinario) desarrollado en [&hellip;]<\/p>","protected":false},"author":1,"featured_media":473,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7,31],"tags":[10,19,36,37],"_links":{"self":[{"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/posts\/472"}],"collection":[{"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/comments?post=472"}],"version-history":[{"count":3,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/posts\/472\/revisions"}],"predecessor-version":[{"id":479,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/posts\/472\/revisions\/479"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/media\/473"}],"wp:attachment":[{"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/media?parent=472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/categories?post=472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vicare.ar\/eng\/wp-json\/wp\/v2\/tags?post=472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}